Ashvattha Therapeuticsincis A Clinical Stage Biopharmaceutical Company Based In Redwood Citycaliforniathe Company Specializes In Developing Precision Nanomedicines Aimed At Treating Various Human Diseaseswith A Focus On Ophthalmologyneurologyand Inflammatory Conditionsone Of Their Notable Productsmigaldendranibis A Nanomedicine That Has Shown Promising Results In Phase 2 Trials For Wet Age Related Macular Degeneration And Diabetic Macular Edema The Company Has A Robust Pipeline Of Potential Products In Clinical Trials And Is Exploring Applications Of Its Nanomedicines In Neurologyparticularly For Treating Neuroinflammation In Conditions Like Multiple Sclerosisashvattha Therapeutics Has Secured Approximately $88 Million In Fundingreflecting Strong Investor Confidence In Its Innovative Approach To Addressing Unmet Medical Needs In Healthcarethe Company Also Actively Engages In Major Conferences To Share Updates On Its Advancements In Nanomedicine Technology
